Moneycontrol Be a Pro
Get App
Last Updated : Jun 13, 2019 01:50 PM IST | Source:

Accumulate Suven Life Sciences; target of Rs 310: Dolat Capital

Dolat Capital recommended Accumulate rating on Suven Life Sciences with a target price of Rs 310 in its research report dated May 28, 2019.

Broker Research @moneycontrolcom
  • bselive
  • nselive
Todays L/H

Dolat Capital's research report on Suven Life Sciences

Suven reported a strong performance during Q4FY19. Revenue grew 19% YoY, due to a 64% YoY rise in specialty chemicals. Core CRAMS grew 4% to ` 718mn, whereas commercial CRAMS fell 23% YoY to ` 420mn (` 800mn for FY19). CTS grew 26% YoY, including Taro royalty worth ` 24mn. The management expects commercial revenue to be in the range of ` 1.3mn in FY20 and flat specialty chemicals. SUVN 502 could be a positive trigger, if the data is favourable.


Based on a conservative approach, we estimate a TP of ` 310 (16x FY21E + NCE pipeline).

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

The Great Diwali Discount!
Unlock 75% more savings this festive season. Get Moneycontrol Pro for a year for Rs 289 only.
Coupon code: DIWALI. Offer valid till 10th November, 2019 .
First Published on Jun 13, 2019 01:50 pm
Follow us on
Available On
PCI DSS Compliant